Measuring metabolites in melanoma patients using advanced techniques
Official title: Measurement of the Metabolome in Melanoma Patients Using NMR Spectroscopy and Gas Chromatography.
Run by Technische Universität Dresden · NCT06765850 · Data updated 2026-11-12
This study is testing if analyzing blood and other body fluids from melanoma patients can help spot the disease earlier and track any changes in their condition.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 3000 (estimated) |
| Sponsor | Technische Universität Dresden Academic / other |
| Locations | 1 site (Dresden, Saxony) |
| Status | Recruiting |
| Started | July 4, 2022 |
| Main results expected | December 2026 |
| Study ends | June 2027 |
| Registry record updated | January 9, 2025 |
| Trial ID | NCT06765850 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals with a current or past history of melanoma who are receiving treatment or follow-up care at the Skin Cancer Centre at Dresden University Hospital.
✕Probably not a fit
Patients who refuse to participate or lack the capacity to consent will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to analyze the metabolome of blood samples and other body fluids from melanoma patients at various stages of the disease, as well as from healthy individuals. By employing NMR spectroscopy and gas chromatography, the study seeks to identify metabolic differences that could aid in the early detection of melanoma, recurrence, or changes in disease stage. The biosamples will be collected at the BioBank Dresden and may be used for additional analyses in the future.
Why it matters
Potential benefit: If successful, this study could lead to improved early detection and monitoring of melanoma, enhancing patient outcomes.
How similar studies have gone: While the approach of using metabolomics for cancer detection is gaining traction, this specific study's methodology is relatively novel and has not been extensively tested in melanoma.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Current or past history of melanoma * Ongoing therapy or tumour aftercare at the Skin Cancer Centre at Dresden University Hospital Exclusion Criteria: * Refusal to participate in the study * Lack of capacity to consent
Where it's running
-
University Hospital Carl Gustav Carus
Dresden, Saxony, Germany Recruiting
Study contacts
- Study coordinator: Frank Friedrich Gellrich, Dr. med.
- Email: frankfriedrich.gellrich@ukdd.de
- Phone: +493514582497
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Personalized adapted exercise program for advanced melanoma
This will try a personalized adapted physical activity program for adults with advanced melanoma who are receiving immunotherapy or targeted therapy.
-
Melanoma in adults aged 18 to 39.
This project will collect clinical, dermoscopic, pathology, and molecular data to see how common melanoma is and what risk factors and skin features it has in people aged 18–39.
-
Combining toripalimab and endostatin for treating stage II melanoma
This study is testing if combining a new cancer drug with another treatment can help people with stage II melanoma live longer without their cancer coming back after surgery.
-
Investigating melanoma in children, adolescents, and young adults
This study is trying to learn more about melanoma in kids, teens, and young adults to help improve how it's diagnosed and treated.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.